Sama Therapeutics is a precision neuropsychiatry AI/ML platform that synthesizes and validates predictive biomarkers grounded in neural, physiological, multi-omics, natural language, and behavioral phenotypes. The company’s agile SaaS platform, iMAGiNE™, analyzes the transdiagnostic efficacy of pharmaceutical and neurostimulation modalities through precision clinical trials, causal inference, preclinical translation, and generative AI trained on proprietary and open-science datasets. With an extraordinarily interdisciplinary team, Sama Therapeutics is advancing “software as medical device” for a range of indications, including cognitive, affective, interoceptive, and substance use disorders.